Effects of GPCRs on Type 2 Diabetes and Obesity

Abstract

The escalating global prevalence of obesity and T2DM presents an increasingly grave challenge to humanity's well-being. These interconnected diseases demand urgent attention and innovative solutions. T2DM and obesity are deeply linked, and the GPCRs is significant in shaping the treatment landscape for both conditions. This article aims to undertaken with the primary goal of delving into the potential of GPCRs as a crucial avenue for addressing and treating obesity and diabetes more effectively. Among the array of GPCRs, GLP-1R emerges as a particularly pertinent player in this context. Presently, among the myriad therapies associated with GPCRs, GLP-1R agonists stand out as the most efficacious. These agonists demonstrate a distinct advantage over other anti-diabetic and anti-obesity medications. Their remarkable attributes include the absence of adverse effects, a diminished risk of hypoglycemia, and the capacity to increase insulin secretion in a way that depends on glucose. These qualities render GLP-1R agonists as a promising therapeutic approach. Furthermore, looking ahead, it is envisioned that GLP-1R agonist treatments will increasingly dominate the landscape of type 2 diabetes and obesity management. Their unique mechanisms and favorable outcomes suggest that GLP-1R agonists will likely emerge as the mainstream and preferred mode of addressing these widespread health concerns.